Due to the coronavirus pandemic, the XXVI EFMC International Symposium on Medicinal Chemistry in Basel has been postponed to August 29 - September 2, 2021.
A 2-days Virtual Event will take place on September 7-8, 2020. Two online Sessions will focus on First Time Disclosures & Late Breaking News. Cutting-edge science will be presented by 9 invited speakers giving you the opportunity to learn about the latest developments while safely remaining at home.
To find out how Instruct-ERIC can benefit your research in medicinal chemistry, join our exhibitor meeting on 7 September, 15:05 CEST.
See the full list of exhibitors here.
QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases
Dr Atwood Cheung
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States
The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis
Dr Andrew Dilger
BRISTOL-MYERS SQUIBB, Princeton, United States
First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases
Dr Riccardo Giovannini
BOEHRINGER INGELHEIM, Biberach, Germany
Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other
Dr Uwe Grether
F. HOFFMANN-LA ROCHE, Basel, Switzerland
The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations
Dr Wooseok Han
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States
Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH
Dr Naoyoshi Noguchi
SCOHIA PHARMA, INC., Fujisawa, Japan
Discovery of AZD8154, a Dual PI3Kγδ Inhibitor, as an Inhaled Treatment for Asthma
Dr Matthew W. D. Perry
ASTRAZENECA, Gothenburg, Sweden
Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy
Dr Norbert Schmees
BAYER PHARMACEUTICALS, Berlin, Germany
GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)
Dr Fredrik Zetterberg
GALECTO BIOTECH, Gothenburg, Sweden
Find the full event programme here.
Registration is now open.
